WB analysis of wild type and IRF3 knock out HeLa cell lysate(10μg per lane) using GTX84287 IRF3 antibody [5D2].
Dilution : 1:500

IHC-P analysis of pancreas tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of lung tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

WB analysis of various cell lines using GTX84287 IRF3 antibody [5D2].
Loading : 35 ug per lane

IHC-P analysis of ovary tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

WB analysis of HEK293T cells transfected with IRF3 plasmid (Right) or empty vector (Left) for 48 hrs using GTX84287 IRF3 antibody [5D2].
Loading : 5 ug per lane

IHC-P analysis of bladder carcinoma tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of endometrium tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of breast adenocarcinoma tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of breast tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of kidney carcinoma tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of prostate carcinoma tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of thyroid carcinoma tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of colon adenocarcinoma tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of pancreas carcinoma tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of thyroid tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

IHC-P analysis of human ovary adenocarcinoma tissue using GTX84287 IRF3 antibody [5D2].
Antigen retrieval : Heat-induced epitope retrieval by 10mM citrate buffer, pH6.0, 100ºC for 10min.
Dilution : 1:50

The data was published in the 2022 in Front Pharmacol. PMID: 35308231